Pentoxifylline as an Adjunct Therapy for Patients With Eisenmenger Syndrome
Eisenmenger Syndrome
About this trial
This is an interventional treatment trial for Eisenmenger Syndrome focused on measuring Pulmonary Hypertension, Congenital Heart Disease, Thrombosis, Pentoxifylline, Thrombomodulin, Tissue Factor
Eligibility Criteria
Inclusion Criteria: Eisenmenger syndrome in functional class II, III or IV (World Health Organization for Pulmonary Hypertension). Using or not oral anticoagulation with warfarin. Exclusion Criteria: Hospitalized. History of relevant and/or repetitive bleeding. Relevant comorbidities with specific treatments. Systemic syndromes, except Down syndrome. Candidates for surgical treatment of any nature, except dental. Clinically manifest systemic infectious or inflammatory disease. Thrombocytopenia (<80x10*9 platelets/L). Patients in chronic anticoagulation regimen other than warfarin. Diabetics individuals. Pregnancy in progress, interruption of contraception or amenorrhea. History of intolerance of pentoxifylline or other xanthine derivatives. "Creatinine clearance" less than or equal to 30 mL/minute.
Sites / Locations
- Antonio Augusto Barbosa LopesRecruiting
Arms of the Study
Arm 1
Arm 2
No Intervention
Other
No treatment group
Pentoxifylline
24 patients that will continue receiving routine treatment for PAH
24 patients that will receive pentoxifylline and the routine treatment for PAH